News from seqirus A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Jun 22, 2022, 17:30 ET CDC Advisory Committee Includes FLUAD® QUADRIVALENT as a Preferentially Recommended Influenza Vaccine for Adults 65 and Older

Seqirus, a global leader in influenza prevention and a business of CSL Limited (ASX:CSL), today announced that the U.S. Centers for Disease Control...

Jun 06, 2022, 08:30 ET Seqirus Completes $156 Million Expansion to Holly Springs Manufacturing Facility, Optimizing Global Manufacturing Capabilities for Seasonal and Pandemic Influenza Vaccines

Seqirus, a global leader in influenza prevention and a business of CSL Limited (ASX:CSL), today announced the completion of an expansion to the...

Jun 02, 2022, 08:30 ET Seqirus' Holly Springs Manufacturing Facility Designated by U.S. Government as Pandemic Ready

Seqirus, a global leader in influenza prevention and a business of CSL Limited (ASX: CSL), today announced that the company's manufacturing facility...

Feb 25, 2022, 08:30 ET Seqirus and U.S. Government Renew Multi-Year Agreement for Influenza Pandemic Preparedness and Response

Seqirus, a global leader in influenza prevention and a business of CSL Limited (ASX:CSL), today announced the renewal of a five-year agreement with...

Feb 07, 2022, 08:30 ET Seqirus, a Business of CSL Limited, Announces New Facility Supporting Research & Development of Leading-Edge Influenza Vaccine Technology

Seqirus, a global leader in influenza prevention and a business of CSL Limited (ASX:CSL), today announced an investment in a new Research and...

Dec 07, 2021, 13:00 ET New Data Supports the Effectiveness of Adjuvanted Seasonal Influenza Vaccine in Reducing Influenza-Related Hospitalizations and Healthcare Costs in Older Adults

Seqirus, a global leader in influenza prevention and a business of CSL Limited (ASX:CSL), today announced new real-world evidence (RWE) supporting...

Nov 23, 2021, 08:30 ET Seqirus Announces U.S. FDA Approval for Multi-Dose Vial Presentation of First-Ever Adjuvanted, Cell-Based Pandemic Influenza Vaccine

The FDA has granted approval of multi-dose vial presentation for AUDENZ™ to help protect individuals six months of age and older against influenza...

Oct 19, 2021, 07:30 ET Seqirus Presents New Real-World Evidence Supporting Effectiveness of Differentiated Seasonal Influenza Vaccine Technologies at ISIRV-WHO Virtual Conference 2021

Seqirus, a global leader in influenza prevention and a business of CSL Limited (ASX:CSL), today announced new real-world evidence (RWE) supporting...

Oct 15, 2021, 10:56 ET Seqirus Receives FDA Approval of its Cell-Based Quadrivalent Influenza Vaccine, Expanding the Age Indication to Include Children as Young as Six Months

Seqirus, a global leader in influenza prevention, and a business of CSL Limited (ASX: CSL), today announced that the U.S. Food and Drug...

Oct 14, 2021, 08:00 ET The New England Journal of Medicine Publishes First-of-its-Kind Study on Cell-Based Quadrivalent Seasonal Influenza Vaccine (QIVc) Efficacy in Children and Adolescents ≥2 to <18 Years of Age

Seqirus, a global leader in influenza prevention, and a business of CSL Limited (ASX:CSL), today announced that The New England Journal of Medicine...

Oct 04, 2021, 08:00 ET Seqirus Awarded U.S. Government Contract to Develop Two Pandemic Influenza Vaccines

Seqirus, a global leader in influenza prevention and a business of CSL Limited (ASX:CSL), today announced that the Biomedical Advanced Research and...

Sep 29, 2021, 07:30 ET Seqirus Presents New Real-World Evidence Demonstrating Effectiveness of Cell-Based and Adjuvanted Seasonal Influenza Vaccines at IDWeek 2021

Seqirus, a global leader in influenza prevention and a business of CSL Limited (ASX: CSL), today announced data supporting the effectiveness of both...

Aug 19, 2021, 08:30 ET Seqirus Announces Investment in Next-Generation Influenza Vaccine Technology, Self-Amplifying Messenger RNA (sa-mRNA)

Seqirus, a global leader in influenza prevention and a business of CSL Limited (ASX:CSL), today announced plans to accelerate the development of its...

Jul 30, 2021, 08:30 ET Seqirus Presents New Safety Data Demonstrating Safety of Cell-Based Seasonal Influenza Vaccine on Pregnancy Outcomes

Seqirus, a global leader in influenza prevention and a business of CSL Limited (ASX:CSL), presented findings from a new observational safety study...
Seqirus Begins Shipping Portfolio of Innovative Vaccines for the 2021/22 U.S. Influenza Season

Jul 27, 2021, 08:30 ET Seqirus Begins Shipping Portfolio of Innovative Vaccines for the 2021/22 U.S. Influenza Season

Seqirus offers a differentiated portfolio of influenza vaccines, including FLUCELVAX® QUADRIVALENT (Influenza Vaccine), the first and only cell-based ...

Jun 14, 2021, 16:05 ET Seqirus Co-Authors First Study to Assess Simultaneous Administration of Seasonal Influenza Vaccine and COVID-19 Vaccine Candidate

Seqirus, a global leader in influenza prevention and a division of CSL Limited (ASX: CSL), today announced that the company co-authored the first...

May 03, 2021, 09:05 ET Seqirus Presents New Phase 3 Clinical Data Supporting Use of Cell-Based Seasonal Influenza Vaccine in Children Six Months Through <4 Years of Age

Seqirus, a global leader in influenza prevention, presented new Phase 3 clinical data demonstrating that the company's cell-based quadrivalent...

Apr 20, 2021, 08:30 ET Seqirus Publishes New Real-World Evidence Supporting the Effectiveness of Adjuvanted Seasonal Influenza Vaccine in Adults 65 Years and Older in Clinical Infectious Diseases

Seqirus, a global leader in influenza prevention, today announced the publication of new real-world evidence (RWE) on the company's MF59® adjuvanted, ...

Mar 25, 2021, 08:30 ET New Seqirus Data Published in Vaccines Highlight Effectiveness and Economic Benefit of Cell-Based Quadrivalent Seasonal Influenza Vaccine (QIVc) in the 2018/19 U.S. Influenza Season

Seqirus, a global leader in influenza prevention, today announced the publication of new real-world evidence (RWE) on the company's cell-based...

Mar 05, 2021, 08:30 ET Seqirus Announces U.S. FDA Approval of Expanded Age Indication of Its Cell-Based Quadrivalent Influenza Vaccine for People Two Years of Age and Older

Seqirus, a global leader in influenza prevention, today announced that the U.S. Food and Drug Administration (FDA) has approved FLUCELVAX®...

Dec 09, 2020, 08:30 ET Seqirus Presents Real-World Data for Cell-Based Quadrivalent Seasonal Influenza Vaccine (QIVc) at ESWI 2020

Seqirus, a global leader in influenza prevention, today presented new real-world evidence (RWE) at the European Scientific Working Group on Influenza ...

Dec 07, 2020, 08:30 ET Seqirus Presents New Data at ESWI 2020 Demonstrating Safety and Immunogenicity of Adjuvanted, Cell-Based Pandemic Influenza A (H5N1) Vaccine

Seqirus, a global leader in influenza prevention and influenza pandemic response, today announced the presentation of new data at the European...

Dec 07, 2020, 08:00 ET Seqirus Presents New Late-Breaking Data at ESWI 2020 Highlighting Benefits of MF59®-Adjuvanted Seasonal Influenza Vaccine

Seqirus, a global leader in influenza prevention and influenza pandemic response, today announced new late-breaking data from a systematic review and ...

Oct 29, 2020, 12:00 ET Seqirus Presents First-of-its-Kind Study on Cell-Based Quadrivalent Influenza Vaccine (QIVc) Efficacy in Children ≥2 to <18 Years Old at the European Society for Paediatric Infectious Diseases (ESPID)

Seqirus, a global leader in influenza prevention, today presented absolute efficacy data on the company's cell-based quadrivalent influenza vaccine...

Oct 21, 2020, 09:00 ET Seqirus Presents New Real-World Evidence on Relative Effectiveness of Adjuvanted Seasonal Influenza Vaccine in Adults 65 Years and Older at IDWeek 2020

Seqirus, a global leader in influenza prevention, today presented new real-world evidence (RWE) on the effectiveness of an MF59®-adjuvanted,...